Hendijani Fatemeh
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Cytotherapy. 2015 May;17(5):509-25. doi: 10.1016/j.jcyt.2014.10.015. Epub 2015 Jan 17.
Cancer treatment plans mainly include chemotherapy, radiotherapy and surgery, which exert serious adverse reactions immediately or during the long term after cancer therapy in many patients. In several cases, treatment-related adverse effects outweigh treatment benefits and worsen the patient's condition. This problem is not avoidable with current cancer therapy procedures; therefore, improved understanding and earlier prevention and reversion of treatment-related complications are particularly important before the lesions become progressive and irreversible. Mesenchymal stromal cell therapy is very promising in recent clinical research and investigations. Their potential properties such as regenerative and reparative functions and anti-inflammatory activity make them proper candidates for cell therapy to recover cancer patients from treatment-related adverse effects or may even prevent them. This article discuss benefits of applying human mesenchymal stromal cell therapy after current cancer treatment plans, with the purpose of prevention and healing of adverse reactions, faster patient recovery after radio/chemotherapy, reducing rates of treatment failure and cancer recurrence and increasing patient quality of life after treatment cessation.
癌症治疗方案主要包括化疗、放疗和手术，在许多患者中，这些治疗会在癌症治疗期间或长期产生严重的不良反应。在某些情况下，与治疗相关的不良反应超过了治疗益处，使患者病情恶化。当前的癌症治疗程序无法避免这个问题；因此，在病变进展和不可逆转之前，更好地理解并更早地预防和逆转与治疗相关的并发症尤为重要。间充质基质细胞疗法在最近的临床研究和调查中非常有前景。它们的潜在特性，如再生和修复功能以及抗炎活性，使其成为细胞疗法的合适候选者，以帮助癌症患者从与治疗相关的不良反应中恢复，甚至可能预防这些不良反应。本文讨论了在当前癌症治疗方案后应用人源间充质基质细胞疗法的益处，目的是预防和治愈不良反应，使患者在放化疗后更快恢复，降低治疗失败和癌症复发率，并提高治疗结束后患者的生活质量。
